NOTCH1 mutation status as a prognostic biomarker in T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
039 patients.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] These findings support incorporating NOTCH1 mutation status into clinical prognostication and treatment planning for T-ALL, potentially facilitating more personalized therapeutic strategies. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-152…
[BACKGROUND] The prognostic significance of NOTCH1 mutations in T-cell acute lymphoblastic leukemia (T-ALL) remains uncertain.
- 95% CI 0.51–0.78
APA
Al Kuwari H, Al Khinji A, et al. (2025). NOTCH1 mutation status as a prognostic biomarker in T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.. BMC cancer, 25(1), 1820. https://doi.org/10.1186/s12885-025-15233-2
MLA
Al Kuwari H, et al.. "NOTCH1 mutation status as a prognostic biomarker in T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.." BMC cancer, vol. 25, no. 1, 2025, pp. 1820.
PMID
41291497 ↗
Abstract 한글 요약
[BACKGROUND] The prognostic significance of NOTCH1 mutations in T-cell acute lymphoblastic leukemia (T-ALL) remains uncertain. This study evaluates their impact on key clinical outcomes.
[METHODS] A systematic search of the Cochrane Library, PubMed, and CINAHL identified eleven peer-reviewed studies encompassing 2,039 patients. Data were independently extracted by two reviewers and analyzed using RevMan 5.4.1.
[RESULTS] NOTCH1 mutations were associated with an approximately 22% improvement in event-free survival (EFS) across ten studies (pooled relative risk 0.63, 95% CI: 0.51–0.78), with corresponding EFS rates of 68.8% in NOTCH1-mutated cases versus 53.8% in wild-type cases. Although the improvement in prednisolone response (PR) across three studies was not statistically significant (pooled OR 1.41, 95% CI: 0.44–4.56; = 056), complete remission (CR) rates in three studies were markedly higher in the NOTCH1-mutant group (pooled OR 8.53, 95% CI: 0.86–85.09). Overall survival (OS), evaluated in three studies, tended to be improved in patients with NOTCH1 mutations; however, substantial inter-study heterogeneity precluded definitive conclusions.
[CONCLUSIONS] These findings support incorporating NOTCH1 mutation status into clinical prognostication and treatment planning for T-ALL, potentially facilitating more personalized therapeutic strategies.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15233-2.
[METHODS] A systematic search of the Cochrane Library, PubMed, and CINAHL identified eleven peer-reviewed studies encompassing 2,039 patients. Data were independently extracted by two reviewers and analyzed using RevMan 5.4.1.
[RESULTS] NOTCH1 mutations were associated with an approximately 22% improvement in event-free survival (EFS) across ten studies (pooled relative risk 0.63, 95% CI: 0.51–0.78), with corresponding EFS rates of 68.8% in NOTCH1-mutated cases versus 53.8% in wild-type cases. Although the improvement in prednisolone response (PR) across three studies was not statistically significant (pooled OR 1.41, 95% CI: 0.44–4.56; = 056), complete remission (CR) rates in three studies were markedly higher in the NOTCH1-mutant group (pooled OR 8.53, 95% CI: 0.86–85.09). Overall survival (OS), evaluated in three studies, tended to be improved in patients with NOTCH1 mutations; however, substantial inter-study heterogeneity precluded definitive conclusions.
[CONCLUSIONS] These findings support incorporating NOTCH1 mutation status into clinical prognostication and treatment planning for T-ALL, potentially facilitating more personalized therapeutic strategies.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15233-2.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.
- Bayes factor hypothesis testing in meta-analyses: Practical advantages and methodological considerations.
- Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer.
- Clinical, Dermatoscopic, Histological and Molecular Prognostic and Predictive Factors of Metastatic Melanoma Response to Immunotherapy: A Systematic Review and Drug Class Meta-Analysis.
- Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.
- Mastitis as a risk factor for breast cancer: a systematic review and meta-analysis.